Psoriasis

Experts in dermatology share final thoughts on the treatment of plaque psoriasis and the ever-changing treatment landscape.

Benjamin Lockshin, MD, FAAD, highlights diversity in clinical trials as an unmet need in approaching the treatment of plaque psoriasis.

Melodie Young, MSN, ANP-c, shares pearls on why prioritizing skin checks during Psoriasis Action Month in August is critical.

Ahmad Amin, MD, FAAD, reviews biologic selection in patients with psoriatic disease.

A poster presented at the 2023 SDPA Annual Summer Dermatology Conference revealed statistically significant improvements among patients with psoriasis receiving brodalumab treatment.

Tj Chao, MPAS, and Lauren Miller, MPAS, discuss tapinarof as a treatment for plaque psoriasis (PP).

Lauren Miller, MPAS, and Tj Chao, MPAS, discuss new treatments for plaque psoriasis (PP) and their mechanisms of action.

Expert dermatologists discuss the treatment guidelines for plaque psoriasis, and how the decision about treatment is ultimately in the hands of the clinician.

Nicholas Brownstone, MD, and James Q. Del Rosso, DO, comment on the psychological impact of plaque psoriasis on a patient’s quality of life.

In one-third of cases of psoriasis, disease onset occurs in the first or second decade of life, although it may not be diagnosed until the patient has reached adulthood.

Lauren Miller, MPAS, PA-C, and Tj Chao, MPAS, PA-C, review how they discuss available treatment options for their plaque psoriasis patients in a recent DermView series.

The current dermatology pipeline includes a wide range of medication classes, from Janus kinase (JAK) inhibitors to tumor necrosis factor inhibitors, to phototherapeutics

Experts discuss the landscape of topical drugs for plaque psoriasis (PP) and key factors in treatment options.

Tj Chao, MPAS, and Lauren Miller, MPAS, highlight treatment efficacy considerations for plaque psoriasis (PP).

Experts in dermatology review a patient case of a 48-year-old man with plaque psoriasis who is having trouble with topical therapy.

Dermatology experts discuss a patient case concerning a 60-year-old woman with chronic intertriginous psoriasis who is taking a biologic drug for inflammatory bowel disease.

Del Rosso and Stein Gold will discuss topical management in an in-depth seminar.

Considering the whole patient is crucial in understanding how natural alternatives can improve the skin.

Lauren Miller, MPAS, and Tj Chao, MPAS, discuss how patient goals and education can inform next steps of treatment for plaque psoriasis (PP).

Experts offer insights on treatment selection and patient education for plaque psoriasis (PP).

Dawn L. Sammons, DO, FAOCD, FAAD, and Benjamin Lockshin, MD, FAAD, review a case of a female patient with a family history of plaque psoriasis.

Experts discuss the unique mechanism of action of tapinarof and its use in the treatment of plaque psoriasis.

The IL-23p19 inhibitor demonstrated long-term efficacy and safety.

Researchers examined the disease while going beyond current diagnostic tools.

Lauren Miller, MPAS, and Tj Chao, MPAS, offer considerations for treating pediatric patients with plaque psoriasis (PP).

Experts discuss plaque psoriasis (PP) treatment options for people who are or may become pregnant.

James Q. Del Rosso, DO, and Dawn L. Sammons, DO, FAOCD, FAAD, review the efficacy of a new topical agent in the treatment of plaque psoriasis, tapinarof, highlighting the remittive data.

Experts in dermatology discuss newer topical treatments, such as tapinarof, in the management of plaque psoriasis.

In patients with high levels of VEGF-A and more severe psoriasis, downregulation of blood vessel area is more abrupt.

Nicholas Brownstone, MD, comments on how newer treatments in plaque psoriasis can impact residency training.